Test warns of breast cancer recurrence
This article was originally published in Clinica
Executive Summary
Blood tests of breast cancer patients can give more than five months' extra warning of tumour recurrence, US researchers report in the Journal of Clinical Oncology (June). The test used, Biomira Diagnostic's Truquant Br Radioimmunoassay, is the first FDA-approved test for use in stage II and stage III breast cancer patients.